Skip to content

Intensive management of infection in high risk leukemia

Effect of sepsis bundle based protocol on clinical outcomes of very high risk febrile neutropenia - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/11/022080
Enrollment
93
Registered
2019-11-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] Health Condition 2: C920- Acute myeloblastic leukemia

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. AML on intensive induction chemotherapy. ii. Relapsed acute leukemia on salvage chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Patient not willing to give consent 2. Acute promyelocytic leukemia 3. Patient with documented infection (clinically/microbiologicaly) at the start of Induction/ salvage chemotherapy.

Design outcomes

Primary

MeasureTime frame
To assess the effect of sepsis bundle based protocol on 30 day mortality among patients with very high risk febrile neutropeniaTimepoint: The data will be collected for the first 30 days of intensive induction treatment

Secondary

MeasureTime frame
To study the clinical outcomes (change in MSOFA score at 48 hours ,occurence of septic shock, organ dysfunction, requirement of ventilatory support) in very high risk febrile neutropenia patients managed with sepsis bundle based protocol. 2.To identify the association of baseline clinical factors, laboratory parameters, profile of infections and pattern of sepsis bundle compliance with 30 day mortality and other clinical outcomes in very high risk febrile neutropenia patients. Timepoint: 30days

Countries

India

Contacts

Public ContactNarendran K

JIPMER

kayalsmita@gmail.com7598118439

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026